

1. Monforte AD, Testa L, Adorni F, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. *AIDS* 1998; 12:1631-7.
2. Wit FW, Van Leeuwen GJ, Jurriaans S, et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency type 1-infected persons. *J Infect Dis* 1999; 179:790-8.
3. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. *Ann Intern Med* 2000; 133:401-410.
4. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. *AIDS* 1999; 13: F35-F43.
5. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virologic failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. *Lancet* 1999; 353: 863-68.
6. Staszewski S, Miller V, Sabin C, et al. Virologic response to protease inhibitor therapy in an HIV clinic cohort. *AIDS* 1999; 13: 367-73.
7. Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. *J Infect Dis* 2000; 182: 1375-84.
8. Khanna N, Klimkait T, Schiffer V, et al. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. *AIDS* 2000; 14: 791-99.
9. Fätkenheuer G, Hoetelmans RM, Hunn N, et al. Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients. *AIDS* 1999; 13: 1485-9.
10. Piketty C, Race E, Castiel P, et al. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. *AIDS* 1999; 13: F71-7.
11. Hall CS, Raines CP, Barnett SH, et al. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. *AIDS* 1999; 13: 1207-12.

12. Deeks SG, Grant RM, Beatty GW, et al. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. *AIDS* 1998; 12: F97-F102.
13. Shulman NS, Zolopa AR, Passaro DJ, et al. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. *JAIDS* 2000; 23: 221-6.
14. Gilbert P, DeGruttola V, and Hammer S. Efficient trial designs for studying combination antiretroviral treatments in patients with various resistance profiles. *J Infect Dis* 1998; 178: 340-8.
15. Paredes R, Puig T, Arno A, et al. High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response. *JAIDS* 1999; 22: 132-8.
16. Khanna N, Klimkait T, Schiffer V, et al. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. *AIDS* 2000; 14: 791-9.
17. Mocroft A, Lundgren JD, and Phillips AN. Response to salvage therapy in patients exposed to all three classes of antiretrovirals: the EuroSIDA study. Third International Workshop on Salvage Therapy for HIV Infection. Chicago, April 2000 [4].
18. Fessel WJ, Follansbee SE, and Young TP. Success rates of salvage treatment after two or more failures of HAART. Third International Workshop on Salvage Therapy for HIV Infection. Chicago, April 2000 [8].
19. Youle M, Phillips A, Loveday C, et al. Prolonged viral suppression after introduction of a post HAART salvage regimen. Third International Workshop on Salvage Therapy for HIV Infection. Chicago, April 2000 [23].
20. Montaner J, Harrigan R, Raboud J, et al. Multi-drug rescue therapy in three cohorts of HIV-positive individuals. Third International Workshop on Salvage Therapy for HIV Infection. Chicago, April 2000 [24].
21. Schooley R, Myers R, Ruane P, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of antiretroviral experienced patients. A double blind, placebo-controlled study. Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 2000 [692].
22. Meynard JL, Vray M, Morand-Joubert L, et al. Impact of treatment guided by phenotypic or genotypic tests on the response to antiretroviral therapy (ART):

a randomised trial (NARVAL, ANRS 088). Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 2000 [698].

23. Walsh JC, Hertogs K, and Gazzard BG. Viral drug resistance, adherence and pharmacokinetic indices in HIV-1 infected patients on successful and failing protease inhibitor (PI) based highly active antiretroviral therapy. Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 2000 [699].
24. Ross LL, Liao Q, Johnson VA, et al. Impact of HIV-1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy in an observational cohort. Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 2000 [1260].
25. Arasteh K, Zwingers T, Sternfeld T, et al. Value of genotyping in heavily pretreated patients (the Berlin Cohort). Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 2000 [1261].